 SUNNYVALE, Calif., March 15, 2022 GLOBE NEWSWIRE -- 23andMe Holding Co. Nasdaq: ME 23andMe, a leading consumer genetics and therapeutics company with a mission to help people access, understand, and benefit from the human genome, today announced that it will present data related to its wholly owned 23ME-00610 immuno-oncology program at the upcoming American Association for Cancer Research AACR 2022 Annual Meeting being held April 8-13, 2022 in New Orleans, Louisiana. 